The Pro12Ala Polymorphism in the Peroxisome Proliferator-Activated Receptor Gamma-2 Gene (PPARγ2) Is Associated with Increased Risk of Coronary Artery Disease: A Meta-Analysis

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Wu, Zhijun ^a   Lou, Yuqing ^b   Jin, Wei ^a   Liu, Yan ^a   Lu, Lin ^a   Lu, Guoping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2;

ARTICLE; ASIAN; CAUCASIAN; CORONARY ARTERY DISEASE; ETHNIC DIFFERENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HOMOZYGOSITY; HOMOZYGOTE; HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2 GENE;

ASIAN CONTINENTAL ANCESTRY GROUP; CORONARY ARTERY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; RISK;

EID: 84871799665     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053105     Document Type: Article

References (65)

1. Ross R, (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126.
2. Duval C, Chinetti G, Trottein F, Fruchart JC, Staels B, (2002) The role of PPARs in atherosclerosis. Trends Mol Med 8: 422-430.
3. Fisman EZ, Tenenbaum A, (2009) A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol 8: 38.
4. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, et al. (2006) International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58: 726-741.
5. Wahli W, Michalik L, (2012) PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab 23: 351-363.
6. Meirhaeghe A, Amouyel P, (2004) Impact of genetic variation of PPARgamma in humans. Mol Genet Metab 83: 93-102.
7. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, et al. (1997) Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 241: 270-274.
8. Tonjes A, Stumvoll M, (2007) The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma in diabetes risk. Curr Opin Clin Nutr Metab Care 10: 410-414.
9. Montagner A, Rando G, Degueurce G, Leuenberger N, Michalik L, et al. (2011) New insights into the role of PPARs. Prostaglandins Leukot Essent Fatty Acids 85: 235-243.
10. Iwata E, Yamamoto I, Motomura T, Tsubakimori S, Nohnen S, et al. (2003) The association of Pro12Ala polymorphism in PPARgamma2 with lower carotid artery IMT in Japanese. Diabetes Res Clin Pract 62: 55-59.
11. Temelkova-Kurktschiev T, Hanefeld M, Chinetti G, Zawadzki C, Haulon S, et al. (2004) Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. J Clin Endocrinol Metab 89: 4238-4242.
12. Al-Shali KZ, House AA, Hanley AJ, Khan HM, Harris SB, et al. (2004) Genetic variation in PPARG encoding peroxisome proliferator-activated receptor gamma associated with carotid atherosclerosis. Stroke 35: 2036-2040.
13. Gouda HN, Sagoo GS, Harding AH, Yates J, Sandhu MS, et al. (2010) The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol 171: 645-655.
14. Zhang H, Zhu S, Chen J, Tang Y, Hu H, et al. (2012) Peroxisome Proliferator-Activated Receptor gamma Polymorphism Pro12Ala Is Associated With Nephropathy in Type 2 Diabetes: Evidence from meta-analysis of 18 studies. Diabetes Care 35: 1388-1393.
15. Namvaran F, Azarpira N, Rahimi-Moghaddam P, Dabbaghmanesh MH, (2011) Polymorphism of peroxisome proliferator-activated receptor gamma (PPARgamma) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes. Eur J Pharmacol 671: 1-6.
16. Chen Z, Vigueira PA, Chambers KT, Hall AM, Mitra MS, et al. (2012) Insulin Resistance and Metabolic Derangements in Obese Mice Are Ameliorated by a Novel Peroxisome Proliferator-activated Receptor gamma-sparing Thiazolidinedione. J Biol Chem 287: 23537-23548.
17. Gurnell M, (2003) PPARgamma and metabolism: insights from the study of human genetic variants. Clin Endocrinol (Oxf) 59: 267-277.
18. Vos HL, Doggen C, Rosendaal FR (2000) Effect of the PPAR gamma2 Pro12Ala polymorphism on the risk of myocardial infarction. Blood 96.
19. Ridker PM, Cook NR, Cheng S, Erlich HA, Lindpaintner K, et al. (2003) Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol 23: 859-863.
20. Doney AS, Fischer B, Leese G, Morris AD, Palmer CN, (2004) Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study. Arterioscler Thromb Vasc Biol 24: 2403-2407.
21. Tobin MD, Braund PS, Burton PR, Thompson JR, Steeds R, et al. (2004) Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. Eur Heart J 25: 459-467.
22. Pischon T, Pai JK, Manson JE, Hu FB, Rexrode KM, et al. (2005) Peroxisome proliferator-activated receptor-gamma2 P12A polymorphism and risk of coronary heart disease in US men and women. Arterioscler Thromb Vasc Biol 25: 1654-1658.
23. Li L, Cheng LX, Nsenga R, He MA, Wu TC, (2006) Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population. Clin Cardiol 29: 300-304.
24. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, et al. (2011) 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 57: e215-367.
25. Joensen AM, Jensen MK, Overvad K, Dethlefsen C, Schmidt E, et al. (2009) Predictive values of acute coronary syndrome discharge diagnoses differed in the Danish National Patient Registry. J Clin Epidemiol 62: 188-194.
26. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, et al. (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123: e426-579.
27. Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, et al. (2005) Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 162: 201-211.
28. Cohn LD, Becker BJ, (2003) How meta-analysis increases statistical power. Psychol Methods 8: 243-253.
29. Lau J, Ioannidis JP, Schmid CH, (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820-826.
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
31. Palanichamy MG, Sun C, Agrawal S, Bandelt HJ, Kong QP, et al. (2004) Phylogeny of mitochondrial DNA macrohaplogroup N in India, based on complete sequencing: implications for the peopling of South Asia. Am J Hum Genet 75: 966-978.
32. Quintana-Murci L, Chaix R, Wells RS, Behar DM, Sayar H, et al. (2004) Where west meets east: the complex mtDNA landscape of the southwest and Central Asian corridor. Am J Hum Genet 74: 827-845.
33. Dragojevič J, Marc J, Mlinar B, (2008) Association between Pro12Ala and His477His polymorphisms in PPARG gene and insulin resistance in patients with polycystic ovary syndrome. Biochemia Medica 18: 342-350.
34. Reich D, Thangaraj K, Patterson N, Price AL, Singh L, (2009) Reconstructing Indian population history. Nature 461: 489-494.
35. Kabagambe EK, Baylin A, Allan DA, Siles X, Spiegelman D, et al. (2001) Application of the method of triads to evaluate the performance of food frequency questionnaires and biomarkers as indicators of long-term dietary intake. Am J Epidemiol 154: 1126-1135.
36. Dallongeville J, Iribarren C, Ferrieres J, Lyon L, Evans A, et al. (2009) Peroxisome proliferator-activated receptor gamma polymorphisms and coronary heart disease. PPAR Res 2009: 543746.
37. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
38. Aydogan HY, Kucukhuseyin O, Tekeli A, Isbir T, (2012) Associations of receptor for advanced glycation end products-374 T/A and Gly82 Ser and peroxisome proliferator-activated receptor gamma Pro12Ala polymorphisms in Turkish coronary artery disease patients. Genet Test Mol Biomarkers 16: 134-137.
39. Yilmaz-Aydogan H, Kurnaz O, Kur O, Akadam-Teker B, Kucukhuseyin O, et al. (2011) Effects of the PPAR-gamma and apolipoprotein E gene polymorphisms on clinical and lipid characteristics in patients with diabetic and non-diabetic coronary heart disease. In Vivo 25: 513-514.
40. Kurnaz O, Yilmaz-Aydogan H, Isbir S, Isbir T, (2011) The effects of PPAR-γ PR012ALA and LOX-1 K167N variants on Turkish coronary artery disease patients. In Vivo 25: 539.
41. Ma RC, Ho JS, Tam CH, Wang Y, Lee HM, et al. (2011) Polymorphism of the PPAR-γ2 gene predicts development of coronary heart disease among chinese subjects with type 2 diabetes. Diabetes 60 (A557).
42. Yilmaz-Aydogan H, Kurnaz O, Kurt O, Akadam-Teker B, Kucukhuseyin O, et al. (2011) Effects of the PPARG P12A and C161T gene variants on serum lipids in coronary heart disease patients with and without Type 2 diabetes. Mol Cell Biochem 358: 355-363.
43. Ho JS, Germer S, Tam CH, So WY, Martin M, et al. (2012) Association of the PPARG Pro12Ala polymorphism with type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population. Diabetes Res Clin Pract.
44. Zee RY, Cook NR, Cheng S, Erlich HA, Lindpaintner K, et al. (2006) Multi-locus candidate gene polymorphisms and risk of myocardial infarction: a population-based, prospective genetic analysis. J Thromb Haemost 4: 341-348.
45. Wang LP, Zhao LR, Cui HW, Yan MR, Yang L, et al. (2012) Association between PPARgamma2 Pro12Ala polymorphism and myocardial infarction and obesity in Han Chinese in Hohhot, China. Genet Mol Res 11.
46. Galgani A, Valdes A, Erlich HA, Mano C, Cheng S, et al. (2010) Homozygosity for the Ala allele of the PPARgamma2 Pro12Ala polymorphism is associated with reduced risk of coronary artery disease. Dis Markers 29: 259-264.
47. AshokKumar M, Veera Subhashini NG, Kanthimathi S, SaiBabu R, Ramesh A, et al. (2010) Associations for lipoprotein lipase and peroxisome proliferator-activated receptor-gamma gene and coronary artery disease in an Indian population. Arch Med Res 41: 19-25 e11.
48. Bluher M, Klemm T, Gerike T, Krankenberg H, Schuler G, et al. (2002) Lack of association between peroxisome proliferator-activated receptor-gamma-2 gene variants and the occurrence of coronary heart disease in patients with diabetes mellitus. Eur J Endocrinol 146: 545-551.
49. Evangelisti L, Attanasio M, Lucarini L, Sofi F, Marcucci R, et al. (2009) PPARgamma promoter polymorphisms and acute coronary syndrome. Atherosclerosis 205: 186-191.
50. Nassar BA, Rockwood K, Kirkland SA, Ransom TP, Darvesh S, et al. (2006) Improved prediction of early-onset coronary artery disease using APOE epsilon4, BChE-K, PPARgamma2 Pro12 and ENOS T-786C in a polygenic model. Clin Biochem 39: 109-114.
51. Rhee EJ, Kwon CH, Lee WY, Kim SY, Jung CH, et al. (2007) No association of Pro12Ala polymorphism of PPAR-gamma gene with coronary artery disease in Korean subjects. Circ J 71: 338-342.
52. Ruiz-Narvaez EA, Kraft P, Campos H, (2007) Ala12 variant of the peroxisome proliferator-activated receptor-gamma gene (PPARG) is associated with higher polyunsaturated fat in adipose tissue and attenuates the protective effect of polyunsaturated fat intake on the risk of myocardial infarction. Am J Clin Nutr 86: 1238-1242.
53. Vogel U, Segel S, Dethlefsen C, Tjonneland A, Saber AT, et al. (2009) PPARgamma Pro12Ala polymorphism and risk of acute coronary syndrome in a prospective study of Danes. BMC Med Genet 10: 52.
54. Zafarmand MH, van der Schouw YT, Grobbee DE, de Leeuw PW, Bots ML, (2008) Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: a case-cohort study and meta-analyses. Vasc Health Risk Manag 4: 427-436.
55. Hemminki K, Lorenzo Bermejo J, Forsti A, (2006) The balance between heritable and environmental aetiology of human disease. Nat Rev Genet 7: 958-965.
56. Fullerton SM, Yu JH, Crouch J, Fryer-Edwards K, Burke W, (2010) Population description and its role in the interpretation of genetic association. Hum Genet 127: 563-572.
57. Salanti G, Sanderson S, Higgins JP, (2005) Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med 7: 13-20.
58. Castelli WP, Garrison RJ, Dawber TR, McNamara PM, Feinleib M, et al. (1981) The filter cigarette and coronary heart disease: the Framingham study. Lancet 2: 109-113.
59. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 283: 2008-2012.
60. Terrin N, Schmid CH, Lau J, Olkin I, (2003) Adjusting for publication bias in the presence of heterogeneity. Stat Med 22: 2113-2126.
61. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I, (2006) The case of the misleading funnel plot. BMJ 333: 597-600.
62. Stumvoll M, Haring H, (2002) The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 51: 2341-2347.
63. Wang N, Yin R, Liu Y, Mao G, Xi F, (2011) Role of peroxisome proliferator-activated receptor-gamma in atherosclerosis: an update. Circ J 75: 528-535.
64. Huang W, Andras IE, Rha GB, Hennig B, Toborek M, (2011) PPARalpha and PPARgamma protect against HIV-1-induced MMP-9 overexpression via caveolae-associated ERK and Akt signaling. FASEB J 25: 3979-3988.
65. Qu A, Shah YM, Manna SK, Gonzalez FJ, (2012) Disruption of endothelial peroxisome proliferator-activated receptor gamma accelerates diet-induced atherogenesis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 32: 65-73.